Eisai sales and marketing update

Eisai launched Inovelon rufinamide oral suspension in Spain for the adjunctive treatment of seizures

Read the full 143 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE